Allergan
2Q Revenues: $4.1 billion (+3%)
2Q Earnings: $2.0 billion (+5%)
FY Revenues: $7.8 billion (+3%)
FY Earnings: $3.7 billion (+7%)
Comments: U.S. Specialized Therapeutics revenues grew 7% in the quarter to $1.8 billion, driven primarily by growth in Medical Aesthetics, including BOTOX Cosmetic, ALLODERM and the addition of CoolSculpting, as well as growth in BOTOX Therapeutic. In Neurosciences & Urology, BOTOX Therapeutic revenues were $404.7 million, up 17%. In Eye Care RESTASIS revenues were $318.2 million, down of 5%. ALPHAGAN/COMBIGAN  revenues were $98.1 million, up 2%. OZURDEX sales were up 11% to $27.6 million. U.S. General Medicine revenues were $1.3 billion, down 8%, impacted by lower revenues from NAMENDA XR  and ESTRACE due to generic competition, offset by growth from VRAYLAR, LINZESS, Lo LOESTRIN and anti-infectives including AVYCAZ.
VRAYLAR sales  grew 72% to $114.2 million. NAMENDA XR sales were $3.4 million, versus $118.7 million in 2Q17, impacted by loss of patent exclusivity in February 2018. LINZESS sales were $191.8 million, up 14% percent. Lo LOESTRIN sales were $127.8 million, up 13%. BYSTOLIC/BYVALSON sales were $148.1 million, down 2%.